---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274506"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:33:25.467506+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Invivyd Q3 net loss $0.36/sh; completes CANOPY Phase 3 enrollment, data expected late 2023/early Q1

## Summary
- Enrolled ~750 participants in CANOPY Phase 3 trial of VYD222 to prevent symptomatic COVID-19.
- Cash, equivalents and marketable securities $264.9M as of Sept 30, 2023; runway into Q4 2024.
- Net loss $39.4M ($0.36 per share) for Q3 2023, compared to $45.1M ($0.42) in Q3 2022.
- VYD222 shows in vitro neutralizing activity against Omicron variants including XBB.1.5.10/EG.5 with F456L mutation.
- Appointed William Duke as CFO on Sept 5, 2023.

## SEC filing metadata
- accession: 0001193125-23-274506
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312523274506/0001193125-23-274506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312523274506/d295277d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274506
- JSON: https://secwatch.observer/filing/0001193125-23-274506.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274506.txt

## Key facts
- Earnings Releases
  Invivyd, Inc. reported quarter ended September 30, 2023 results: net income Net loss was $39.4 million, EPS Basic and diluted net loss per share was $0.36.
  - Period: quarter ended September 30, 2023
  - Net income: Net loss was $39.4 million
  - EPS: Basic and diluted net loss per share was $0.36
  - Result: reported results
  source text: Third Quarter 2023 Financial Results: • Cash position: Cash, cash equivalents and marketable securities were $264.9 million as of September 30, 2023. • Cash runway: Based on current operating plans, Invivyd continues to expect its existing total cash, cash equivalents and marketable securities will enable the company to fund its operating expenses into the fourth quarter of 2024, excluding potential contribution of commercial product revenue if a mAb candidate is authorized or approved. • Research & development (R&D) expenses (including in-process research & development): R&D expenses were $30.2 million for the quarter ended September 30, 2023, compared to $34.1 million for the comparable period of 2022. The decrease is primarily attributable to higher clinical trial costs in 2022 due to ongoing adintrevimab clinical trials, with no comparable costs during the same period in 2023 due to the wind-down of adintrevimab clinical trials, partially offset by clinical trial costs associated w
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312523274506/0001193125-23-274506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.